Global Problem
Pterygium, Pingueculum, and Pyogenic Granulomas are pressing ocular issues affecting millions worldwide. These lesions, driven by excessive VEGF-induced angiogenesis, lead to unwanted tissue growth in the eye. They are notoriously difficult to treat, often damaging the cornea, impairing vision, causing discomfort, and creating distress due to their appearance. Current clinical solutions are limited, with severe cases frequently requiring costly surgical interventions.
Localized Solutions
Our innovative, patented treatment harnesses the power of anti-VEGF technology to tackle these lesions at their root cause. This non-invasive or minimally invasive approach offers a superior alternative to existing and foreseeable treatments, providing patients with effective relief without the need for extensive surgical procedures. Experience a new era of eye care that prioritizes comfort and effectiveness.
Pingueculum & Pterygium have a very high recurrence rate post-surgery. These lesions are due to VEGF causing angiogenesis, which results in unwanted tissue growth in the eye.
Pingueculum
Pterygium
Pyogenic granuloma
Transformative Patient Care
CellViva develops patented, non-invasive and minimally invasive anti-VEGF treatments that outperform existing options by reducing downtime, costs, and recurrence rates with just 1-3 applications.
Our solutions empower clinicians to perform aesthetic and functional procedures in ophthalmology and dermatology on previously ineligible patients. By advancing and refining medical practices, CellViva sets new standards in ocular and dermatological care.
Clear Benefits
CellViva’s innovative minimally-invasive anti-VEGF treatments offer compelling advantages for patients, clinicians, and healthcare systems alike. With just 1-3 applications, these patented solutions significantly reduce downtime, costs, and recurrence rates compared to existing options.
Expand patient access.
Speed up Surfer’s Eye Recovery (pterygium).
